{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:48:17Z","timestamp":1765806497547},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T00:00:00Z","timestamp":1126569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:p><jats:bold>Abstract: Background\/Aims: <\/jats:bold> Prostacyclin (PGI<jats:sub>2<\/jats:sub>) is a potent mediator in the inflammatory and coagulation processes. The aim of this study was to test whether beraprost sodium, a PGI<jats:sub>2<\/jats:sub> analogue, could prevent experimental hepatic injury induced by concanavalin A (Con A), which is a model of fulminant hepatic failure.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Beraprost (100\u2003\u03bcg\/kg) was administered intraperitoneally simultaneously with Con A (40\u2003mg\/kg) in C57B6J mice. Blood circulation in the liver was determined by laser\u2010Doppler flowmetry. Plasma levels of alanine aminotransferase (ALT), tumor necrosis factor (TNF)\u2010\u03b1, interferon (IFN)\u2010\u03b3, and interleukin (IL)\u20106 were determined. Levels of TNF\u2010\u03b1 and IFN\u2010\u03b3 in culture supernatant of splenocytes were also determined.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Beraprost administration reduced the incidence of death following hepatic failure (76.5% vs. 29.4%, <jats:italic>P<\/jats:italic>&lt;0.05). Plasma levels of ALT were significantly lower in the beraprost\u2010treated group than in the control group, and in the former, there was concomitant suppression of the histological features of injury. Beraprost significantly increased hepatic blood flow volume in Con A\u2010treated mice. Plasma levels of TNF\u2010\u03b1 and IFN\u2010\u03b3 were significantly reduced at 6 and 12\u2003h after Con A injection, respectively, but the levels of IL\u20106 were increased at 6\u2003h. <jats:italic>In vitro<\/jats:italic>, beraprost also suppressed Con A\u2010induced TNF\u2010\u03b1 production in splenocytes, while it stimulated IFN\u2010\u03b3 production.<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> These findings imply that beraprost suppresses Con A\u2010induced liver injury. These data also suggest that beraparost, which is clinically effective in treating pulmonary hypertension, may have therapeutic potential for preventing hepatic injury.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2005.01143.x","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T08:00:44Z","timestamp":1126598444000},"page":"1061-1068","source":"Crossref","is-referenced-by-count":14,"title":["Beraprost sodium, a prostacyclin (PGI<sub>2<\/sub>) analogue, ameliorates concanavalin A\u2010induced liver injury in mice"],"prefix":"10.1111","volume":"25","author":[{"given":"Satoshi","family":"Ohta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyuki","family":"Kohjima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munechika","family":"Enjoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Nawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(77)90037-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1978.tb07809.x"},{"key":"e_1_2_7_4_2","first-page":"H176","article-title":"Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver","volume":"238","author":"Araki H","year":"1980","journal-title":"Am J Physiol"},{"key":"e_1_2_7_5_2","first-page":"279","article-title":"Stereoselective synthesis of 5,6,7\u2010trinor\u20104,8\u2010inter\u2010m\u2010phenylene\u2010PGI2 derivatives and their inhibitory activities to human platelet aggregation","volume":"15","author":"Ohno K","year":"1985","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.47.1"},{"key":"e_1_2_7_7_2","first-page":"495","article-title":"Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets","volume":"39","author":"Kajikawa N","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_8_2","first-page":"426","article-title":"Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication","volume":"102","author":"Lievre M","year":"2000","journal-title":"a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00312-5"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00881.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01988-X"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/tri.1992.5.s1.366"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115836"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040566697"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.1.105"},{"key":"e_1_2_7_16_2","first-page":"1529","article-title":"T cell activation\u2010associated hepatic injury","volume":"179","author":"Mizuhara H","year":"1994","journal-title":"mediation by tumor necrosis factors and protection by interleukin 6"},{"key":"e_1_2_7_17_2","first-page":"190","article-title":"Concanavalin A\u2010induced T\u2010cell\u2010mediated hepatic injury in mice","volume":"21","author":"Gantner F","year":"1995","journal-title":"the role of tumor necrosis factor"},{"key":"e_1_2_7_18_2","first-page":"1608","article-title":"Critical involvement of interferon gamma in the pathogenesis of T\u2010cell activation\u2010associated hepatitis and regulatory mechanisms of interleukin\u20106 for the manifestations of hepatitis","volume":"23","author":"Mizuhara H","year":"1996","journal-title":"Hepatology"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8690213"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250614"},{"key":"e_1_2_7_21_2","first-page":"1418","article-title":"Suppression of concanavalin A\u2010induced hepatitis in IFN\u2212\u2212\/\u2212 mice, but not in TNF\u2212\u2212\/\u2212 mice","volume":"159","author":"Tagawa Y","year":"1997","journal-title":"role for IFN- in activating apoptosis of hepatocytes"},{"key":"e_1_2_7_22_2","first-page":"1035","article-title":"Concanavalin A\u2010induced liver cell damage","volume":"114","author":"Trautwein C","year":"1998","journal-title":"activation of intracellular pathways triggered by tumor necrosis factor in mice"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.4049\/jimmunol.160.8.4082","article-title":"Disparate roles for TNF\u2010 and fas ligand in concanavalin A\u2010induced hepatitis","volume":"160","author":"Ksontini R","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_7_24_2","first-page":"315","article-title":"Essential pathogenetic role for interferon (IFN\u2010) in concanavalin A\u2010induced T cell\u2010dependent hepatitis","volume":"12","author":"Nicoletti F","year":"2000","journal-title":"exacerbation by exogenous IFN- receptor-immunoglobulin fusion protein"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70223-X"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.2.1300"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270225"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310115"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203567200"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.802"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1033.2002.03157.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(01)01309-7"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002689900162"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711420110"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00059-4"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000091336.55487.F7"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100740200"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200323651"},{"key":"e_1_2_7_39_2","first-page":"915","article-title":"Arachidonic acid stimulates interleukin\u20106 release from rat peritoneal macrophages in vitro","volume":"49","author":"Holladay C S","year":"1993","journal-title":"evidence for a prostacyclin-dependent mechanism"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI504"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.2.1300"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4570"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040566697"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64804-3"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.1.105"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01143.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2005.01143.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:30:26Z","timestamp":1695889826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2005.01143.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,13]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1478-3231.2005.01143.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01143.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,13]]}}}